Atara Biotherapeutics Inc (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 600 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $30.38, for a total value of $18,228.00. Following the completion of the sale, the chief executive officer now owns 743,675 shares of the company’s stock, valued at approximately $22,592,846.50. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Shares of Atara Biotherapeutics Inc (NASDAQ ATRA) traded down $0.75 during mid-day trading on Friday, reaching $27.50. The company’s stock had a trading volume of 655,000 shares, compared to its average volume of 1,469,842. Atara Biotherapeutics Inc has a 12-month low of $11.80 and a 12-month high of $30.90. The company has a market capitalization of $894.93, a P/E ratio of -7.93 and a beta of 1.27.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.97) by ($0.05). sell-side analysts forecast that Atara Biotherapeutics Inc will post -4 earnings per share for the current fiscal year.

A number of hedge funds have recently made changes to their positions in the business. Dimensional Fund Advisors LP lifted its position in Atara Biotherapeutics by 2.9% in the second quarter. Dimensional Fund Advisors LP now owns 21,718 shares of the biotechnology company’s stock valued at $304,000 after purchasing an additional 610 shares during the last quarter. Teachers Advisors LLC lifted its position in Atara Biotherapeutics by 2.4% in the second quarter. Teachers Advisors LLC now owns 47,156 shares of the biotechnology company’s stock valued at $660,000 after purchasing an additional 1,110 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in Atara Biotherapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock valued at $285,000 after purchasing an additional 1,369 shares during the last quarter. Voya Investment Management LLC lifted its position in Atara Biotherapeutics by 16.2% in the second quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock valued at $165,000 after purchasing an additional 1,651 shares during the last quarter. Finally, Rhumbline Advisers lifted its position in Atara Biotherapeutics by 11.3% in the second quarter. Rhumbline Advisers now owns 31,373 shares of the biotechnology company’s stock valued at $439,000 after purchasing an additional 3,175 shares during the last quarter. Hedge funds and other institutional investors own 69.67% of the company’s stock.

ATRA has been the subject of a number of recent research reports. BidaskClub upgraded Atara Biotherapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, January 11th. Canaccord Genuity restated a “buy” rating on shares of Atara Biotherapeutics in a research report on Friday, December 29th. Goldman Sachs Group restated a “neutral” rating and issued a $20.00 target price on shares of Atara Biotherapeutics in a research report on Friday, October 6th. Jefferies Group restated a “buy” rating and issued a $30.00 target price on shares of Atara Biotherapeutics in a research report on Thursday, October 5th. Finally, Citigroup upgraded Atara Biotherapeutics from a “sell” rating to a “neutral” rating and set a $18.00 target price for the company in a research report on Wednesday, January 3rd. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Atara Biotherapeutics has an average rating of “Buy” and an average target price of $30.60.

ILLEGAL ACTIVITY NOTICE: This article was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.thecerbatgem.com/2018/01/19/isaac-e-ciechanover-sells-600-shares-of-atara-biotherapeutics-inc-atra-stock.html.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.